Etiology and Prognostic Analysis of Acute Liver Failure in Chinese Children

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age28-18
Sponsorliyumei

About this trial

Research Background:

Pediatric acute liver failure (PALF) refers to the sudden onset of severe liver injury in children without known chronic liver disease, leading to multi-system organ dysfunction, with a mortality rate as high as 50%-70%. The etiology of PALF is complex and varied, including infections, metabolic disorders, and toxins. In developed countries, it is often caused by drug and toxin exposure, while in developing countries, viral infections are the primary cause. Additionally, 30%-50% of PALF cases have an unknown etiology, which increases the difficulty of treatment. Current treatment options include medical management, artificial liver support, and liver transplantation. Liver transplantation is the only proven effective treatment, but issues such as organ shortages and the timing of transplantation affect treatment outcomes. Improving diagnostic capabilities for the etiology and exploring optimal treatment strategies are of significant importance in enhancing the clinical success rate of PALF management.

Research Objective:

To explore the etiology and prognostic factors of pediatric acute liver failure (PALF), analyze the relationship between different causes of PALF and prognosis, and the relationship between different treatment modalities and prognosis. This study aims to investigate the correlation between etiology, treatment methods, and outcomes, providing scientific evidence to improve the precision in diagnosis and treatment of PALF and to enhance decision-making and timing judgments for liver transplantation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

For patients who were admitted twice, only the information from the first hospitalization will be used.

Patients with a history of chronic liver disease (e.g., genetic metabolic factors, drug-induced factors) or biliary obstruction that led to the acute episode are categorized under acute liver failure.

The child's legal guardian has signed a written informed consent form.

Disqualifiers

Age > 18 years;

Significant data missing (>10%);

The child's legal guardian refuses participation.

Trial population

Criteria for Diagnosing Pediatric Acute Liver Failure

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

400 Participants
are grouped into 1 trial group
Group A: Criteria for Diagnosing Pediatric Acute Liver Failure

Trial outcomes

Primary outcomes

1

Discharge Status

Cured: * Clinical symptoms such as bleeding tendency and hepatic encephalopathy disappear; * Jaundice resolves (TBil ≤ 2× upper limit of normal); ③ Liver function markers return to baseline; ④ PTA/INR normalizes. Improved: ① Significant improvement in clinical symptoms like bleeding, and disappearance of hepatic encephalopathy; * Significant improvement in jaundice, ascites, and other physical signs; ③ Liver function markers show marked improvement (TBIL \< 5× upper limit of normal, PTA \> 40% or INR \< 1.5). Worsened: No improvement in symptoms or signs of liver failure, liver function deteriorates, and complications increase or worsen. Death or death within one week after withdrawal of treatment. Liver Transplantation.

Time frame
At discharge (within 1 week)

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

liyumei

Lead sponsor

The First Hospital of Jilin University

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: